Drug intelligence / Profile preview

UI082

Development stage: Preclinical
Lead developer: Korea United Pharm
Modality: Small Molecules
Administration: Oral

Overview

UI082 is an incrementally modified drug (IMD) candidate being developed by Korea United Pharm as a lipid-modifying agent. It is a small molecule fixed-dose combination of pitavastatin, an HMG-CoA reductase inhibitor (statin), and fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-alpha) agonist. This combination is designed to treat mixed dyslipidemia by simultaneously reducing LDL cholesterol and triglycerides while increasing HDL cholesterol levels. UI082 is currently in the formulation development stage, utilizing Korea United Pharm's expertise in drug delivery systems to optimize the stability and bioavailability of the combined active ingredients.

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on UI082.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI082.

Explore the full profile